Trial Profile
A retrospective,cohort study to evaluate the incidence and risk factors of cytomegalovirus associated with low dose Valganciclovir prophylaxis in kidney transplant recipients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 May 2017
Price :
$35
*
At a glance
- Drugs Valganciclovir (Primary)
- Indications Cytomegalovirus infections
- Focus Therapeutic Use
- 11 May 2017 New trial record
- 03 May 2017 Results assessing eight year outcomes of low dose Valganciclovir presented at the 2017 American Transplant Congress.